Screened 2026-09-09 · the tape above runs as of 17:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Illumina Inc. holds its Markup at $205.00. The statistical read favours the sellers, held for 120 days.
As held on the ledger · 2026-09-09
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 120 days
Price at the screen
$205.00
Valuation
38.25 trailing · 33.58 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.47
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio 38.4%
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
38.43%
Below 33%
Interest-bearing debt is 38.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
21.34%
Below 33%
Cash held in interest-bearing accounts and securities is 21.3% of assets, under the one-third limit.
Pass
Receivables
12.85%
Below 49%
Money owed to the company is 12.9% of assets, under the 49% limit.
Pass
Revenue purity
1.40%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades above our $160.61 fair value estimate, 9.40% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. The price runs 21.7% above the base estimate.
Third-party analyst targets: 19 covering, consensus Buy. The average target sits +4% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Gene Sequencing Leader Fails Price and Ethics Test
Every time a researcher unlocks a new genetic insight, Illumina's tools sit at the centre of the process. The company dominates the sequencing market, yet that dominance has not translated into sensible pricing or clean books.
We pass for two clear reasons. The shares sit at 186 dollars while fair value lands at 125 dollars, leaving no margin of safety. It also fails the ethical screen on a 38 percent debt ratio, which is precisely what the screen is designed to catch.
Forward earnings sit at 31 times while revenue grows only 5 percent a year. That gap leaves scant room for disappointment in a space facing rising competition and tighter research budgets. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ILMN trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-02Markup$219.40+13.7%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 85%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (19 analysts) rates it buy, with a mean price target of $144.
2026-08-02Markup$192.98+18.9%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 85%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (19 analysts) rates it buy, with a mean price target of $144.
2026-07-18Markup$162.32+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 85%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (19 analysts) rates it buy, with a mean price target of $144.
2026-07-03Markup$162.32+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$162.32Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
